Evidence-based recommendations of a national group of experts on the use of methotrexate in inflammatory rheumatic diseases;Evidenzbasierte empfehlungen einer nationalen expertenrunde zum einsatz von methotrexat bei entzundlich-rheumatischen erkrankungen

Aktuelle Rheumatologie

Volumn 34, Issue 1, 2009, Pages 59-66

  Tarner, I H ^a,b   Manger, B ^a,c   Fleck, M ^a,d   Gromnica Ihle, E ^a,e   Keyfsser G ^a,f   Kohler L ^a,g   Kotter I ^a,h   Kruger K ^a,i   Kuipers, J ^a,j   Lorenz, H M ^a,k   Nusslein H ^a,l   Rau, R ^a,m   Rubbert, A ^a,n   Schroder J O ^a,o   Wollenhaupt, J ^a,p   Muller Ladner U ^a,b  

^a Die Institutsangaben Sind am Ende des Beitrags Gelistet ^*  (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Asklepios Klinikum Bad Abbach   (Germany)

^e MARTIN LUTHER KRANKENHAUS   (Germany)

^f Klinik und Poliklinik fur Innere Medizin   (Germany)

^g Internist / Rheumatologe   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ Praxiszentrum Rheumatologie   (Germany)

^j Medizinische Klinik   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l Internist / Rheumatologe   (Germany)

^m Internist/Rheumatologe   (Germany)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^o UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^p Allgemeines Krankenhaus Eilbek   (Germany)

more..

Author keywords

Dosing; Folic acid; Methotrexate; Monitoring; Pregnancy

Indexed keywords

METHOTREXATE;

DRUG INDICATION; EVIDENCE BASED MEDICINE; GOLD STANDARD; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

EID: 62649141300     PISSN: 0341051X     EISSN: 14389940     Source Type: Journal    
DOI: 10.1055/s-0028-1119370     Document Type: Review

References (125)

1. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22 (2): 218-223
2. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39 (5): 723-731
3. Alarcon GS, Kremer JM, Macaluso M et al. Risk factors for metho- trexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127 (5): 356-364
4. Alarcon GS, Tracy IC, Strand GM et al. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 1995; 54 (9): 708-712
5. Aletaha D, Stamm T, Kapral T et al. Survival and effectiveness of le- flunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62 (10): 944-951
6. Aponte J, Petrelli M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 1988; 31 (12): 1457-1464
7. Arias JM, Morton KA, Albro JE et al. Comparison of methods for identifying early methotrexate-induced hepatotoxicity in patients with rheumatoid arthritis. J Nucl Med 1993; 34 (11): 1905-1909
8. Assous N, Touze E, Meune C et al. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Joint Bone Spine 2007; 74 (1): 66-72
9. Beyeler C,Jordi B, Gerber NJ et al. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1996; 35 (5): 446-452
10. Beyeler C, Reichen J, Thomann SR et al. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997; 36 (3): 338-344
11. Bjorkman DJ, Boschert M, Tolman KG et al. The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis . Arthritis Rheum 1993; 36 (12): 1697-1701
12. Bjorkman DJ, Hammond EH, Lee RG et al. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis . Arthritis Rheum 1988; 31 (12): 1465-1472
13. Boh LE, Schuna AA, Pitterle ME et al. Low-dose weekly oral metho- trexate therapy for inflammatory arthritis. Clin Pharm 1986; 5 (6): 503 - 508
14. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of me- thotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58 (1): 73-81
15. Brick JE, Moreland LW, Al-Kawas F et al. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients . Semin Arthritis Rheum 1989 ; 19 : 31 - 44
16. Callen JP. Dermatomyositis. Lancet 2000; 355 (9197): 53-57
17. Capell HA, Madhok R, Porter DR et al. Combination therapy with sul- fasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007 ; 66 (2) : 235 - 241
18. Caporali R, Cimmino MA, Ferraccioli G et al. Prednisone plus metho- trexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141 (7): 493-500
19. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26 (6): 1275-1279
20. Carpenter MT, West SG, Vogelgesang SA et al. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 1996; 19 (3): 207-210
21. Carvallo A, Wolff C, Armas R et al. Rheumatoid arthritis. Therapeutic efficacy of methotrexate and its hepatotoxic effects. Rev Med Chil 1993; 121 (7): 777-784
22. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30 (2): 241-246
23. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002 ; 359 (9313) : 1173 - 1177
24. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66 (1): 34-45
25. Conaghan PG, Crotty M, Oh E et al. Anti-rheumatic drug-prescribing behaviour of Australasian rheumatologists 1984-1994. Br J Rheuma- tol 1997 ; 36 (4) : 487 - 490
26. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126 (5): 376380
27. Cottin V, Tebib J, Massonnet B et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109 (4): 933 - 938
28. Criswell LA, Henke CJ. What explains the variation among rheuma- tologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995; 22 (5): 829835
29. La Mata J De, Blanco FJ, Gomez-Reino JJ. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis 1995 ; 54 (11) : 881 - 885
30. Donnenfeld AE, Pastuszak A, Noah JS et al. Methotrexate exposure prior to and during pregnancy. Teratology 1994 ; 49 (2) : 79 - 81
31. Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis . Arthritis Rheum 2002 ; 46 (9) : 2294 - 2300
32. Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58 (4): 220-225
33. Erickson AR, Reddy V, Vogelgesang SA et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients . Arthritis Rheum 1995; 38 (8): 1115-1119
34. Fathi NH, Mitros F, Hoffman J et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis . J Rheumatol 2002 ; 29 (10) : 2092 - 2098
35. Ferraccioli G, Salaffi F, Vita S De et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23 (4): 624-628
36. Flowers MA, Heathcote J, Wanless IR et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990 ; 112 (5) : 381 - 382
37. Fortin PR, Abrahamowicz M, Ferland D et al. Study of methotrexate in lupus erythematosus (SMILE): significant decreased disease activity and steroid sparing effect in patients without damage. Arthritis Rheum 2001; 44 (Suppl): S387
38. Franklin J, Lunt M, Bunn D et al. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006; 65 (5): 617-622
39. Fries JF, Williams CA, Ramey D et al. The relative toxicity of disease- modifying antirheumatic drugs. Arthritis Rheum 1993; 36 (3): 297 -306
40. Furst DE, Koehnke R, Burmeister LF et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16 (3): 313-320
41. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS et al. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999; 26 (11): 2337-2343
42. Golden MR, Katz RS, Balk RA et al. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22 (6): 1043-1047
43. Grennan DM, Gray J, Loudon J et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001 ; 60 (3) : 214 -217
44. Griffith SM, Fisher J, Clarke S et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) 2000; 39 (10): 1102-1109
45. Groff GD, Shenberger KN, Wilke WS et al. Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum 1983; 12 (4): 333-347
46. Grove ML, Hassell AB, Hay EM et al. Adverse reactions to disease- modifying anti-rheumatic drugs in clinical practice. Qjm 2001; 94 (6) : 309 - 319
47. Gutierrez-Urena S, Molina JF, Garcia CO et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39 (2) : 272 - 276
48. Haagsma CJ, Riel PL van, Jong AJ de et al. Combination of sulphasala- zine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36 (10): 1082-1088
49. Hagiyama H, Kubota T, Komano Y et al. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis . Clin Exp Rheumatol 2004 ; 22 (3) : 375 - 376
50. Hall PD, Ahern MJ, Jarvis LR et al. Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. Ann Rheum Dis 1991 ; 50 (7) : 471 - 476
51. Hetland ML, Stengaard-Pedersen K, Junker P et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betame- thasone compared with methotrexate and intraarticular betametha- sone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006 ; 54 (5) : 1401 - 1409
52. Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983 ; 75 (6A): 69 - 73
53. Ichikawa Y, Saito T, Yamanaka H et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005 ; 15 (5) : 323 - 328
54. Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001 ; 44 (2) : 339 - 342
55. Kay EA, Pullar T. Variations among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs. Br J Rheumatol 1992 ; 31 (7) : 477 - 483
56. Kent PD, Luthra HS, Michet C et al. Risk factors for methotrexate-in- duced abnormal laboratory monitoring results in patients with rheumatoid arthritis . J Rheumatol 2004 ; 31 (9) : 1727 - 1731
57. Kozlowski RD, Steinbrunner JV, MacKenzie AH et al. Outcome of first- trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88 (6): 589-592
58. Kremer JM, Alarcon GS, Lightfoot Jr RW et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994 ; 37 (3) : 316 -328
59. Kremer JM, Furst DE, Weinblatt ME et al. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996 ; 23 (3) : 459 - 461
60. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial . Ann Intern Med 2002 ; 137 (9) : 726 - 733
61. Kremer JM, Kaye GI, Kaye NW et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables . Arthritis Rheum 1995 ; 38 (9) : 1194 - 1203
62. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986 ; 29 (7) : 822 - 831
63. Kremer JM, Lee RG, Tolman KG . Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989 ; 32 (2) : 121 - 127
64. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992; 35 (2): 138-145
65. Lehman AJ, Esdaile JM, Klinkhoff AV et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005 ; 52 (5) : 1360 - 1370
66. Leonard PA , Clegg DO, Carson CC et al. Low dose pulse methotrexate in rheumatoid arthritis: an 8-year experience with hepatotoxicity. Clin Rheumatol 1987 ; 6 (4) : 575 - 582
67. Lewden B, Vial T, Elefant E et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 2004; 31 (12): 2360-2365
68. Mackenzie AH. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis. Cleve Clin Q 1985; 52 (2): 129-135
69. Maetzel A, Wong A, Strand V et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease- modifying anti-rheumatic drugs . Rheumatology (Oxford) 2000 ; 39 (9) : 975 - 981
70. Mahr ADJoverJA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007 ; 56 (8) : 2789 - 2797
71. MarchesoniA, Battafarano N, Arreghini M et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and metho- trexate with methotrexate alone. Rheumatology (Oxford) 2003 ; 42 (12): 1545-1549
72. Mariette X, Cazals-Hatem D, Warszawki Jet al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99 (11): 3909-3915
73. Mckendry RJ, Freeman C, Dale P. AST and/or ALT for methotrexate monitoring . Arthritis Rheum 1995 ; 38 (Suppl) : 680
74. Minocha A, Dean HA, Pittsley RA. Liver cirrhosis in rheumatoid arthritis patients treated with long-term methotrexate. Vet Hum To- xicol 1993; 35 (1): 45-48
75. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992 ; 19 (5) : 704 - 708
76. Morgan SL, Baggott JE, Vaughn WH et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121 (11): 833 - 841
77. Morgan SL, Baggott JE, Vaughn WH et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33 (1): 9-18
78. Murata K, Yasuda T, Ito H et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 2006; 16 (1): 14-19
79. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD et al. Severe hepatitis linked to B virus infection after withdrawal of low dose me- thotrexate therapy. J Rheumatol 1998 ; 25 (10) : 2037 - 2038
80. O'Dell JR, Elliott JR, Mallek JA et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus metho- trexate alone. Arthritis Rheum 2006; 54 (2): 621-627
81. ODell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334 (20): 1287-1291
82. grendik M. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. South Med J 2007; 100 (2): 135-139
83. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheu- matol 2000 ; 27 (8) : 1872 - 1875
84. Ostensen M, Esebeck M vaon, Villiger PM. Therapy with immunosup- pressive drugs and biological agents and use of contraception in patients with rheumatic disease J Rheumatol 2007; 34 (6): 1266-1269
85. Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62 (7) : 686 - 687
86. Papadopoulos NG, Alamanos Y, Papadopoulos IA et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long- term observational study. J Rheumatol 2002; 29 (2): 261-266
87. Pappalardo A, Salli L, Compagno M. Efficacy and tolerability of methotrexate in the treatment of rheumatoid arthritis]. Clin Ter 1998; 149 (2): 109-114
88. Pavy S, Constantin A, Pham T et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion . Joint Bone Spine 2006 ; 73 (4) : 388 - 395
89. Phillips CA, Cera PJ, Mangan TF et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992 ; 19 (2) : 229 - 233
90. Pincus T, Yazici Y, Sokka T et al. Methotrexate as the anchor drug for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003 ; 21 (5 Suppl 31) : S179 - S185
91. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists . J Rheumatol 2002 ; 29 (2) : 255 - 260
92. Ramanan AV, Campbell-Webster N, Ota S et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52 (11): 3570 - 3578
93. Rau R, Karger T, Herborn G et al. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with me- thotrexate. J Rheumatol 1989; 16 (4): 489-493
94. Richard S, Guerret S, Gerard F et al. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system . Rheumatology (Oxford) 2000 ; 39 (1): 50-54
95. Roddy E, Zhang W, Doherty M et al. Evidence-based clinical guidelines: a new system to better determine true strength of recommendation . J Eval Clin Pract 2006 ; 12 (3) : 347 - 352
96. Ros S, Juanola X, Condom E et al. Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand J Rheumatol 2002 ; 31 (6) : 330 - 336
97. Sackett DL, Richardson WS, Rosenberg WM et al. Evidence-based medicine: how to practice and teach EBM . London (UK): Churchill Livingstone; 1997
98. Sany J, Anaya JM, Canovas F et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993; 20 (7): 1129-1132
99. Schnabel A, Reinhold-Keller E, Willmann V et al. Tolerability of me- thotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994 ; 14 (1) : 33 - 38
100. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate therapy for rheumatoid arthritis. Semin Arthritis Rheum 1991; 20 (5): 317331
101. Shergy WJ, Polisson RP, Caldwell DS et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988; 85 (6): 771-774
102. Sidiropoulos PI, Hatemi G, Song IH et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3e Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008 ; 47 (3) : 355 - 361
103. Song IH, Rudwaleit M, Marker-Hermann E et al. Praktische Hinweise zur Diagnostik, zum Monitoring und zur Therapie der ankylosie- renden Spondylitis: Ergebnisse aus Deutschland im Rahmen der sog. 3e-Initiative. Akt Rheumatol 2007 ; 32 : 229 - 234
104. Soubrier M, Dubost JJ, Ristori JM. Polymyalgia rheumatica: diagnosis and treatment . Joint Bone Spine 2006 ; 73 (6) : 599 - 605
105. Suzuki Y, Uehara R, Tajima C et al. Elevation of serum hepatic ami- notransferases during treatment of rheumatoid arthritis with low- dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 1999; 28 (5): 273-281
106. Szanto E, Sandstedt B, Kollberg B. Hepatotoxicity associated with low- dose, long-term methotrexate treatment of rheumatoid arthritis. Scand J Rheumatol 1987; 16 (4): 229-234
107. Taqweem MA, Ali Z, Takreem A et al. Methotrexate induced hepato- toxicity in rheumatoid arthritis patients . J Postgrad Med Inst 2005 ; 19 : 387 - 391
108. Tascioglu FO, Oner C, Armagan O. Comparison of low dose metho- trexate and combination therapy with methotrexate and sulpha- salazine in the treatment of early rheumatoid arthritis. J Rheumatol Med Rehabil 2003; 14: 142-149
109. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006; 26 (2) : 55 - 62
110. Tishler M, Caspi D, Halperin Z et al. A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term metho- trexate therapy. Rheumatol Int 1992; 12 (1): 39-41
111. Tolman KG, Clegg DO, Lee RG et al. Methotrexate and the liver. J Rheu- matol 1985 ; 12 (Suppl 12) : 29 - 34
112. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclo- sporine and methotrexate in severe rheumatoid arthritis. The Me- thotrexate-Cyclosporine Combination Study Group . N Engl J Med 1995; 333 (3): 137-141
113. Ede AE van, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44 (7): 1515-1524
114. Halm VP van, Nurmohamed MT, Twisk JW et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006 ; 8 (5) : R151
115. Tulder M van, Furlan A, Bombardier C et al. Updated method guidelines for systematic reviews in the cochrane collaboration back review group . Spine 2003 ; 28 (12) : 1290 - 1299
116. Verstappen SM, Jacobs JW, Veen MJ van der et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) . Ann Rheum Dis 2007 ; 66 (11): 1443-1449
117. Walker AM, Funch D, Dreyer NA et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis . Arthritis Rheum 1993 ; 36 (3) : 329 - 335
118. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37 (10): 1492-1498
119. Weinblatt ME, Maier AL, Fraser PA et al. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998 ; 25 (2) : 238 - 242
120. Weinstein A, Marlowe S, Korn J et al. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am J Med 1985 ; 79 (3) : 331 - 337
121. Willkens RF, Leonard PA , Clegg DO et al. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis 1990; 49 (8): 591-593
122. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50 (6): 1740-1751
123. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45 (11): 1370-1375
124. WongJM, EsdaileJM. Methotrexate in systemic lupus erythematosus. Lupus 2005; 14 (2): 101-105
125. Yazici Y, Erkan D, Harrison MJet al. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities . Clin Exp Rheumatol 2005 ; 23 (4) : 517 - 520